Effects of ShenFu Injection on Peripheral Neurotoxicity of Paclitaxel

XIONG Shao-quan, ZOU Xiao-ling, ZHENG Qiao. et al

Abstract

To investigate the effects and the underlying mechanisms of ShenFu Injection on paclitaxel-induced peripheral neuropathy. Methods Twenty-eight adult male Wister rats were randomized into 4 groups (rt= 7): control group* paclitaxel group, paclitaxel combined with low or high dose of ShenFu Injection groups. Rats were intraperitoneally injected with paclitaxel 8 mg/kg every 4 d for a total of 4 doses except control group. From Day 1 of the experiment (injection), low dose (4 mL/kg) and high dose (8 mL/kg) of Shenfu Injection were intraperitoneally injected daily in the combination groups for a total of 21 d respectively, while normal saline (NS) was injected in control group in the same way instead. Mechanical withdraw threshold (MWT) and thermal withdraw latency (TWL) of rats’ hind paw were measured before (0 d) and after the first injection (6 d, 14 d). The level of nerve growth factor (NGF) in the serum was measured at 22 d before the euthanasia, and the ultrastructure of the sciatic nerve was observed with transmission electron microscope. Results The MWT and TWL of 14 d in paclitaxel group significantly increased compared with those of 0 d and control group (P<0. 05). The combination of paclitaxel with ShenFu Injection, especially the high dose (P<0.05), significantly reduced the MWT and TWL when compared to paclitaxel group at 14 d. Compared with simultaneous control group, there was no remarkably increased MWT and TWL in the low and high dose of ShenFu Injection (P>0.05). Compared with control group, the serum NGF level significantly decreased (P<0. 05) in paclitaxel group, while the serum NGF level in low and high dose of ShenFu Injection groups were higher than paclitaxel group, particularly in the high dose group (P<0. 05). When compared to control group, the sciatic nerve fiber structure in the paclitaxel group was generally damaged, including myelin sheath swelling, fragmentation and vacuolization, endoplasmic reticulum swelling and matrix structure disorder in Schwann cells. The structural damages were mitigated in the low dose and high dose groups, especially the latter one, when compared to the paclitaxel group. Conclusion Shenfu Injection can reduce the peripheral neurotoxicity of paclitaxel by promoting the expression of NGF in serum.


Keywords: ShenFu Injection Paclitaxel Peripheral neuropathy NGF


Full Text:

PDF


References


STAFF NP. GRISOLD А, GRISOLD W, et al. Chemotherapy-induced peripheral neuropathy; a current review. Ann Neurol.2017,81 (6);772-781.

JAMIE R, GLADYS M. ELIEEN D, et al. Chemotherapy- induced peripheral neuropathy; current status and progress. Gynecol Oncol, 2016,140( 1); 176-183.

JESSICA A, EDGAR T. PATRICK M. Mechanism involved in the development of chemotherapy-induced neuropathay. Pain Manag. 2015,5(4) :285-296.

BRAMI С. BAO T. DENG G. Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy; a systematic review. Crit Rev Oncol Hematol. 2016,2(98);325-334.

LU Y.LIU LN.LOU HG. et al. Shenfu injection protects against myelosuppression from chemotherapy. J Chinese Pharmac Sci, 2012,21 (4): 345-349

ARRIETA 6. HERNANDEZ-PEDRO N. FERNANDEZ- GONZALEZ-ARAGON MC, et al. Retinoic acid reduces chemotherapy-induced neuropathy in an animal model and patients with lung cancer. Neurology. 2011 .77(10);987-995.

SMITH EM. PANG H. CIRRINCIONE C, et al. Effect of duloxetine on pain. function .and quality of life among patients with chemotherapy-induced painful peripheral neuropathy :a randomized clinical trail. JAMA.2013.309(13): 1359-1367.

CRIOROIU С . WEIMER LH. Update on chemotherapy- induced peripheral neuropathy. Curr Neurol Neurosci Rep. 2017,17(6) :47-50.

TAILLIBERT S, LE RHUN E. CHAMBERLAIN MC. Chemotherapy-related neurotoxicity. Curr Neurol Neurosci Rep,2016, 16(9); 1-14.

HOPKINS HL. DUGGETT NA. FLATTERS SJL. Chemotherapy-induced painful neuropathy; pain-like behaviours in rodent models and their response to commonly- used analgesics. Curr Opin Support Palliat Care, 2016, 10 (2):119-128.

CAVALETTI G, PEZZONI G, PISANO С, et al. Cisplatin- induced peripheral neurotoxicity in rats reduces the circulating levels of nerve growth factor. Neurosci Lett, 2002, 322 ( 2 ): 103-106.

GAVALETTI G. PETRUCCIOLI MG, MARMIROLI P. et al. Circulating nerve growth factor level changes during oxaliplatin treatment-induced neurotoxicity in the rat. Anticancer Res,2002,22(6c):4199-4204.

ZHANG К. ZHANG Y. ZHU H. et al. High expression of MACC1 predicts poor prognosis in patients with osteosarcoma. Tumor Biol.2014 .35(2): 1343-1350.

STEIN U. SMITH J. WAI-THER W. et al. MACC1 controls Met: what a difference an Spl site makes. Cell Cycle. 2009,8(15):2467-2469.

ARLT F, STEIN U. Colon cancer metastasis; MACC1 and Met as metastatic pacemakers. Int J Biochem Cell Biol.2009, 41(12);2356-2359.

LUO W. LIN SC. Axin: a master scaffold for multiple signaling pathways. Neurosignals,2004.133(3) :99-113.

NAKAMOTO M, MATSUYAMA A, SHI BA E. et al. Prognostic significance of WNT signaling in pancreatic ductal adenocarcinoma. Virchows Arch,2014 .465(4 );401-408.

HE Y, LIAN G, LIN S, et al. Mdm2 inhibits Axin-induced p53 activation independently of its E3 ligase activity. PLoS One,2013,8(6): e67529[2017-03-25]. https://doi. org/10. 1371 journal, pone. 0067529.

MENG F, LI H, SHI H. et al. MACC1 down-regulation inhibits proliferation and tumourigenicity of nasopharyngeal carcinoma cells through Akt/p- catenin signaling pathway. PLoS One. 2013. 8 ( 4 ): e60821 [2017-03-25]. https://doi. org/10. 1371 /journal, pone. 0060821.

GAOJ. DING F. LIU Q. et al. Knockdown of MACC1 expression suppressed hepatocellular carcinoma cell migration and invasion and inhibited expression of MMP2 and MMP9. Mol Cell Biochem,2013,376(1/2) ;21-32.

XUE H, SUN K. XIE W. et al. Etanercept attenuates short-term cigarette-smoke-exposure-induced pulmonary arterial remodelling in rats by suppressing the activation of TNF-a/NF-kB signal and the activities of MMP-2 and MMP- 9. Pulm Pharmacol Ther,2012,25(3)

XIE С, WU J, YUN J, et al. MACCl as a Prognostic biomarker for early-stage and afp-normal hepatocellular carcinoma. PLoS One, 2013, 8 ( 5 ): e64235 [ 2017-03-25 ]. https://doi. org/10. 1371/journal, pone. 006423.

YAMAMOTO H, MIYOSHI N, MIMORI K. et al. MACCl expression levels as a novel prognostic marker for colorectal cancer. Oncol Lett,2014,8(5) :2305-2309.


Refbacks

  • There are currently no refbacks.